Intellia Therapeutics

Yahoo Finance • 5 days ago

Aramark To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. BMO Capital raised the price target for Nextpowe... Full story

Yahoo Finance • 7 days ago

Intellia Therapeutics GAAP EPS of -$0.81 beats by $0.08, revenue of $15.04M beats by $1.23M

* Intellia Therapeutics press release [https://seekingalpha.com/pr/20508834-intellia-therapeutics-announces-first-quarter-2026-financial-results-and-business-updates] (NTLA [https://seekingalpha.com/symbol/NTLA]): Q1 GAAP EPS of -$0.81 b... Full story

Yahoo Finance • 7 days ago

Cathie Wood buys $12.9 million of tumbling tech stock

Cathie Wood, chief of Ark Investment Management, is known for making bold bets on fast-moving tech stocks. Sometimes her trades move just as quickly as the stocks themselves. In the week that began on May 3, Wood sold millions of dollars... Full story

Yahoo Finance • 13 days ago

Cathie Wood Dumps $72 Million of AMD, Doubles Down on Alphabet and Meta

This article first appeared on GuruFocus. Cathie Wood's ARK Invest shifted cash into several large-cap technology names and AI-linked growth stocks while trimming exposure to semiconductors and crypto-related products, according to the fu... Full story

Yahoo Finance • 18 days ago

Cathie Wood Loads Up $14 Million on Alphabet Just Before Earnings

This article first appeared on GuruFocus. Cathie Wood's ARK Invest funds bought Alphabet (NASDAQ:GOOGL), CoreWeave (NASDAQ:CRWV), Intellia Therapeutics (NTLA) and Kratos Defense & Security Solutions on Tuesday, while trimming Bullish (NYS... Full story

Yahoo Finance • 20 days ago

Intellia Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today an... Full story

Yahoo Finance • 20 days ago

Intellia Successfully Edited Genes Inside The Body. Why Shares Aren't Flying.

Intellia Therapeutics could soon win Food and Drug Administration approval for the first-ever drug that edits genes inside a patient's body. Continue Reading... Full story

Yahoo Finance • 23 days ago

Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026

World’s first Phase 3 readout for an in vivo CRISPR gene editing candidateCompany to host webcast to discuss data at 8:00 a.m. ET on April 27, 2026 CAMBRIDGE, Mass., April 24, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq... Full story

Yahoo Finance • last month

The Credibility Filter Wall Street Uses to Sort Biotech Winners

VANCOUVER, British Columbia, April 08, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary — Biotechs that went public in Q1 2026 raised a median of $287.5 million each; and nearly every one of them carried mid or late stage clinic... Full story

Yahoo Finance • last month

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today an... Full story

Yahoo Finance • 2 months ago

This Cathie Wood Stock Is Up 47% This Year: Is It Too Late to Buy?

Cathie Wood, the CEO of the investment management firm Ark Invest, is known for focusing on companies with significant innovative potential. One of her firm's picks, Intellia Therapeutics(NASDAQ: NTLA), fits the bill. Intellia is a mid-ca... Full story

Yahoo Finance • 2 months ago

Roblox initiated, Target upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Telsey Advisory upgraded Target (TGT)... Full story

Yahoo Finance • 2 months ago

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Cathie Wood seems to always be making market moves. The founder and CEO of Ark Invest publishes her transactions at the end of every trading day, and that gives us all a great way to track one of the most widely followed growth investors.... Full story

Yahoo Finance • 3 months ago

Intellia Therapeutics, Inc. (NTLA): A Bull Case Theory

We came across a bullish thesis on Intellia Therapeutics, Inc. on Danny’s Substack by Danny Green. In this article, we will summarize the bulls’ thesis on NTLA. Intellia Therapeutics, Inc.'s share was trading at $12.48 as of February 18th.... Full story

Yahoo Finance • 3 months ago

Intellia outlines 2026 lonvo-z launch plans as FDA lifts clinical hold on MAGNITUDE-2

Earnings Call Insights: Intellia Therapeutics (NTLA) Q4 2025 MANAGEMENT VIEW * CEO John Leonard highlighted that "with up to 3 years of patient follow-up, we have yet to see any waning of effect in serum kallikrein or TTR levels in the... Full story

Yahoo Finance • 3 months ago

H.C. Wainwright Boosts Intellia (NTLA) Price Target After MAGNITUDE-2 Hold Lifted

Intellia Therapeutics, Inc. (NASDAQ:NTLA) ranks among the best innovative stocks to buy according to Wall Street analysts. H.C. Wainwright reiterated a Buy rating on Intellia Therapeutics, Inc. (NASDAQ:NTLA) while boosting its price target... Full story

Yahoo Finance • 3 months ago

Global Gene Therapy and CRISPR Market Shows Billion Dollar Growth with Novartis Zolgensma 1.2 Billion Sarepta Elevidys 611 Million and Emerging CRISPR Collaborations 20 Million

Precedence Research Precedence Research, a leading strategic research firm, today released a comprehensive overview of the gene therapy and CRISPR therapeutics market, highlighting key company performance, pipeline developments, and gover... Full story

Yahoo Finance • 3 months ago

This Cathie Wood Stock Is Already Up 41% This Year, But Is It a Buy?

Cathie Wood, the CEO of Ark Invest, is known for investing in companies with strong innovative potential. That includes biotechs that specialize in gene editing, a group of techniques that could revolutionize medicine by helping researcher... Full story

Yahoo Finance • 3 months ago

Baird Updates Intellia Therapeutics, Inc. (NTLA)’s Financial Model Following Nex-Z Clinical Hold Removal

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. Intellia Therapeutics, Inc. is positioned seventh on our list. TheFly reported on January 28 that Baird raised its price target on NTLA to $7 from $4 while ma... Full story

Yahoo Finance • 5 months ago

What Makes Intellia Therapeutics (NTLA) an Interesting Investment?

Contrarius Investment Management, an investment management company, released its third-quarter investor letter for the “Contrarius Global Equity Fund”. A copy of the letter can be downloaded here. The fund’s investor class returned 30.9% i... Full story